Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global Clinical Research Organizations in 2021| ADC, precision and deep cultivation for targeted drug delivery| What are the three major in vitro pharmacokinetic research methods?
Jul 22,2021
Medicilon appoints Dr. Xuedong Dai as Executive Vice President of International Discovery Service Unit
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Xuedong Dai as Executive Vice President of International Discovery Service Unit. Dr. Xuedong Dai Executive Vice President of International Discovery Service Unit Dr. Xuedong Dai, Ph.D. in Organic Chemistry and Postdoctoral at MIT, has been deeply involved in the research and developmentRead more
More
Medicilon appoints Dr. Xuedong Dai as Executive Vice President of International Discovery Service Unit
Jul 22,2021
What is Accelerated Stability Testing?
The accelerated stability test places perishable products under stress to estimate the shelf life under normal conditions. In this test, the company encourages the product to fail in a short period of time in harsh environments, and use this to estimate what might happen under normal conditions. This eliminates the need to store the productRead more
More
What is Accelerated Stability Testing?
Jul 22,2021
New star in protein targeted degradation technology-LYTAC
Targeted protein degradation technology (Proteolysis TArgeting Chimeras, PROTAC) is an emerging hot drug development area following small molecule inhibitors (SMI) and monoclonal antibody (mAb) drugs. Compared with the latter two, PROTAC has unique advantages, being able to target numerous protein molecules that were previously considered "undruggable”. Hundreds of PROTAC molecules have been or are beingRead more
More
New star in protein targeted degradation technology-LYTAC
Jul 21,2021
The Second Generation LYTAC Technology
Targeted protein degradation is a very promising treatment, and it is also an important tool for discovering cell biology pathways and apoptosis mechanisms. Many methods for targeted protein degradation have been established, such as targeted induced protein degradation technology (PROTAC), autophagy targeted chimera (AUTAC), etc., but most of these methods target proteins in the cytoplasm.Read more
More
Jul 21,2021
PROTAC and LYTAC
Most drugs block or modulate the function of the target protein by binding to a specific site of the target protein. However, the activity of many proteins cannot be changed in this way. Protein degradation agents represented by Proteolis-Targeting Chimaeras (PROTACs) can change the function of proteins in an unconventional way. This new type ofRead more
More
Jul 13,2021
Ligand Binding Analysis of Drug Screening Methods
The acquisition of lead compounds and the production of drugs are important links in the process of drug screening. Drug screening involves a series of steps to select the most suitable chemical entity for drug development to clinical application, including pharmacological research and toxicological research. Research to determine the safety and effectiveness of the drug.Read more
More
Ligand Binding Analysis of Drug Screening Methods
Jul 13,2021
Caenorhabditis elegans, a model animal for studying the regulation of serotonin in the brain
With the continuous improvement of biological science and technology, the current models constructed using model organisms are playing an increasingly important role in drug screening. Patients with depression and anxiety often have lower levels of serotonin in their bodies. For these patients, some drugs that increase serotonin levels are often used clinically. Serotonin, also knownRead more
More
Caenorhabditis elegans, a model animal for studying the regulation of serotonin in the brain
Jul 13,2021
Scientists have discovered a new anti-cancer drug-EBV protein inhibitor
Epstein-Barr virus (EBV) is a herpes virus that is pathogenic to humans. It has been found to be associated with nasopharyngeal cancer, some gastric cancer, laryngeal cancer and Hodgkin's lymphoma. Although the proportion of EB virus directly causing cancer is very low, because of the high proportion of human infections, the eradication of cancer causedRead more
More
Jul 13,2021
Aloe-emodin inhibits tumor cell activity
Anthraquinone compounds are one of the important active components of aloe, which mainly include aloe emodin, chrysophanol, emodin, rhein acid and emodin methyl ether. A large number of cell experiments have shown that the anthraquinone compound aloe emodin can inhibit tumor cell proliferation and induce tumor cell apoptosis by blocking cell cycle. Therefore, the researchRead more
More
Aloe-emodin inhibits tumor cell activity
Jul 13,2021
The role of in vitro MTT experiment in preclinical efficacy evaluation of anticancer drugs
Practical methods for evaluating tumor cell growth and survival are very important in tumor research.In preclinical efficacy evaluation of antitumor drugs, in vitro MTT pharmacodynamics experiments are often used to explore the inhibitory effect of compounds on the growth of tumor cells in vitro, or in vivo tumor transplantation pharmacodynamics experiments are used to exploreRead more
More
The role of in vitro MTT experiment in preclinical efficacy evaluation of anticancer drugs